BCL2 and breast cancer: SFN also increases paclitaxel-induced apoptosis in breast CSCs by activating extrinsic/intrinsic signaling pathway caspase-3, −8, and −9 members, as well as cytochrome C [6]. Further, the compound reduces the expression of apoptosis regulator Bcl-2 protein which otherwise inhibits the effectiveness of other breast cancer treatments [6].